• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert

    3/21/24 9:20:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email

    REDWOOD CITY, CA / ACCESSWIRE / March 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading Technology-as-a-Service (TaaS) company revolutionizing the medical diagnostic and consumer healthcare field, announces it partnership with Health Aid Africa, one of the most highly anticipated charity concerts for healthcare access and awareness.

    Experience the rhythm of life like never before at the Health Aid Africa charity concert, where the thrill of music meets the heart of wellness, thanks to a pioneering partnership with Biotricity Inc. Set against the backdrop of the world's most renowned stadium, this event offers more than just spectacular musical acts-it presents a life-saving opportunity. Engage with Biotricity's cutting-edge wearable heart monitors and state-of-the-art diagnostic tools to receive invaluable heart health insights.

    This collaboration marks a significant leap forward in making sophisticated cardiac care accessible to all. Join us in a celebration that transcends entertainment, empowering you to connect with your heart's health while losing yourself in the rhythm of inspiring performances. Don't miss this unique blend of exhilaration and enlightenment-your ticket to the concert is also your key to a healthier heart.

    The Health Aid Africa concert, a pioneering initiative to fund an innovative hospital equipped with the latest in health technology, promises to bring quality medical care to those in underserved areas. This grand endeavor is led by Eddie Tantoco & Elora Tran of Eye on Channel, Dustin Salinas of Rasha LTD Inc., and Andre Roberson of the Power of One Foundation, showcasing a remarkable blend of healthcare, technology, and philanthropy. Set to take place at the magnificent Allegiant Stadium, with a seating capacity of 65,000, the event is also geared to captivate billions across the globe through live stream and broadcast channels. The production will be enhanced with live-streaming talent cutaways, bridging continents from Africa to Asia, Europe, Australia, Singapore, the UK, and beyond, ensuring a truly global experience. By being part of this monumental event, you're not just witnessing a spectacular showcase of music and technology; you're supporting a noble cause that extends far beyond the concert's final note. Join us in this transformative journey to uplift and provide for those who need it most.

    Dr. Jere Rivera-Dugenio of Rasha LTD Inc. will contribute significantly by providing a Rasha dome and the JustGoingViral platform. The Rasha dome will serve as a vital preparatory space for performers, ensuring they are in optimal condition before their stage appearances. The JustGoingViral platform is an integrated business solution powered by the leading marketing tools and AI, guaranteeing that news of the heart health screening initiative reaches a wide audience.

    Further amplifying Health Aid Africa's impact, Silicon Valley HQ, will provide free upskilling opportunities - including webinars and mentorship - to empower the next generation of African students and entrepreneurs. SiliconValleyHQ is a virtual ecosystem that provides proprietary startup templates, mentorship access to 150+ experts, industry insights and a virtual acceleration program.

    Elevate your brand at the Health Aid Africa concert, a unique blend of music, wellness, and philanthropy. This high-profile event offers your brand unparalleled exposure to millions worldwide and a direct connection with a diverse, engaged audience. By sponsoring, your brand will not only be showcased across global platforms but will also align with a powerful cause, enhancing your corporate image. Participate in interactive booths, product demos, and direct consumer engagement in a vibrant, feel-good environment.

    Join us in making a significant impact while placing your brand at the heart of innovation and compassion. Be more than a logo; be a leader in change with https://healthaidafrica.com

    For Investors interested in learning more about Biotricity, its robust revenue trajectory, and its comprehensive suite of medical diagnostic and consumer healthcare technologies, visit www.biotricity.com/investors.

    About Biotricity

    Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.

    Important Cautions Regarding Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

    Investor Relations Contacts

    [email protected]

    SOURCE: Biotricity, Inc.



    View the original press release on accesswire.com

    Get the next $BTCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

    REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter

    11/14/25 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th

    REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financial performance. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors. Event: B

    11/7/25 8:30:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    SEC Filings

    View All

    SEC Form S-1 filed by Biotricity Inc.

    S-1 - BIOTRICITY INC. (0001630113) (Filer)

    12/22/25 5:29:37 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOTRICITY INC. (0001630113) (Filer)

    11/18/25 4:05:51 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Biotricity Inc.

    10-Q - BIOTRICITY INC. (0001630113) (Filer)

    11/14/25 3:38:49 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosa David A

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/15/23 4:22:52 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Al-Siddiq Waqaas

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/14/23 4:26:54 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ayanoglou John

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/13/23 4:10:59 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biotricity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Biotricity from Buy to Neutral

    11/20/23 7:21:43 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Biotricity with a new price target

    Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

    3/7/22 9:01:18 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Biotricity with a new price target

    HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

    11/23/21 6:29:32 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Financials

    Live finance-specific insights

    View All

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

    REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter

    11/14/25 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th

    REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financial performance. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors. Event: B

    11/7/25 8:30:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biotricity Inc.

    SC 13G - BIOTRICITY INC. (0001630113) (Subject)

    8/8/24 6:09:48 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care